SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.
Ontology highlight
ABSTRACT: The current pandemic of coronavirus disease 2019 (COVID-19), transmitted person-to-person by severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2), poses a threat to global public health. To present, these are still no clinically approved antibodies or drugs specific for SARS-CoV-2, which makes it difficult for controlling the associated pandemic, limited to monitoring and containment. This situation generates a new need for the development of safe and effective treatments. Since SARS-CoV-2 shares phylogenetic traits with SARS-CoV and MERS-CoV, antiviral medicines may provide some insight into the development of COVID-19 therapeutics. Besides that, they are being prioritized several FDA-approved drugs due to the pandemic state. Despite recent advances in the control of the current COVID-19 pandemic, challenges such as the rapid virus spread and the socioeconomic cost of this outbreak remain for the inexistence of therapeutics agents against SARS-CoV-2. From this moment, the in vivo evaluation of FDA-approved drugs, which until then appears to be effective are recommended, such as chloroquine, hydroxychloroquine, remdesivir, favipiravir, nitazoxanide, and ivermectin; besides new targets: Mpro, spike glycoprotein, and TMPRSS2 inhibitors. Therefore, these investigations are needed to prove the efficacy and safety of these potential candidates, including their side effects.
SUBMITTER: Campos DMO
PROVIDER: S-EPMC7675315 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA